Equity Overview
Price & Market Data
Price: $7.14
Daily Change: -$0.30 / 4.20%
Daily Range: $7.02 - $7.49
Market Cap: $68,544,000
Daily Volume: 200,611
Performance Metrics
1 Week: 6.25%
1 Month: -11.52%
3 Months: -25.77%
6 Months: -30.27%
1 Year: -55.38%
YTD: -15.20%
Company Details
Employees: 152
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.